Shilpa granted license to market ticlopidine hydrochloride in Europe

By Elaine Rigoli

Tampa, Fla., March 27 - Shilpa Medicare Ltd. has received a license from the European Directorate for the Quality of Medicines (EDQM) for an active pharmaceutical ingredient, ticlopidine hydrochloride, an antithrombotic used as an inhibitor of platelet aggregation.

With this approval, Shilpa can explore commercial options in Europe, according to a company news release.

The company has also filed drug master files for Buflomedil hydrochloride and is preparing to file several drug master files for oncology products with the endorsement from the EDQM.

Shilpa, based in Raichur, India, is a research and development pharmaceutical product development company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.